BridgeBio's KRAS-focused cancer spinout backs SPAC as path to Nasdaq
For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. While interest in this path has died down in recent years, BridgeBio’s former cancer unit thinks it could work for them.
For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. While interest in this path has died down in recent years, BridgeBio’s former cancer unit thinks it could work for them.
